Chinese Population Health and Multimorbidity Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Chronic Respiratory Diseases, Cardiovascular and Cerebrovascular Diseases, Malignant Tumors, Endocrine and Metabolic Diseases. Basic parameters: from 20 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Chinese Population Health and Multimorbidity Study: Baseline Survey, and Follow-up Investigation
Overview
The Chinese Population Health and Multimorbidity Study (CPHMS; initially named China Pulmonary Health Study, CPHS) was a large-scale epidemiological survey designed to investigate the pulmonary health of Chinese adults aged 20 years or older leveraging a multistage stratified sampling scheme between 2011 and 2014 in mainland China. Briefly, a total number of 57,779 local residents were recruited from 10 representative provinces and municipalities and were invited to participate in the study. A final number of 50,991 adults who met the major inclusion criteria could be considered in further analyses. In order to investigate the changes of pulmonary health and disease status (e.g. occurrence and development of chronic respiratory diseases and other important relevant multimorbidities, lung function indices, etc.) and corresponding impact factors in the CPHMS study population, we plan to initiate the first round of follow-up investigation between 2025 and 2027 (planned) , i.e. more than 10 years after the baseline survey.
Primary outcome measures
- Occurrence of multimorbidities [Time frame: Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)]
Secondary outcome measures (4)
- Changes of lung function, forced expiratory volume in one second (FEV1) [Time frame: Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)]
- Changes of lung function, forced vital capacity (FVC) [Time frame: Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)]
- Changes of lung function, FEV1/FVC [Time frame: Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)]
- Changes of lung function, the percentage of measured FEV1 value to the predicted value (FEV1%pred) [Time frame: Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)]
Eligibility criteria
Inclusion criteria
- (1) the individuals who participated in the CPHMS baseline survey;
- (2) their ID number and phone number are available;
- (3) sign the informed consent.
Exclusion criteria
- (1) incapable of taking pre- and post-bronchodilator spirometry tests;
- (2) request to withdraw the informed consent;
- (3) terminate due to medical or ethical considerations judged by the investigators and/or ethics committee.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- China-Japan Friendship Hospital — Beijing
Publications
- Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Huang K, Yao W, Sun T, Shan G, Yang T, Lin Y, Wu S, Zhu J, Wang R, Shi Z, Zhao J, Ye X, Song Y, Wang Q, Zhou Y, Ding L, Yang T, Chen Y, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Xiao D, Chen CS, Wang Z, Zhang H, Bu X, Zhang X, An L, Zhang S, Cao Z, Zhan Q, Yang Y, Cao B, Dai H, Liang L, He J; China Pulmonary Health Study Group. PMID 29650248
- Huang K, Yang T, Xu J, Yang L, Zhao J, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Chen Y, Sun T, Shan G, Lin Y, Xu G, Wu S, Wang C, Wang R, Shi Z, Xu Y, Ye X, Song Y, Wang Q, Zhou Y, Li W, Ding L, Wan C, Yao W, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Xiao D, Wang Z, Chen Z, Bu X, Zhang H, Zhang X, An L, Zhang S, Zhu J, Cao Z, Zhan Q, Yang Y, Liang L, Tong X, Dai H, Cao B, Wu T, Chung KF, He J, Wa PMID 31230828
- Xiao D, Chen Z, Wu S, Huang K, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Yao W, Sun T, Shan G, Yang T, Lin Y, Zhu J, Wang R, Shi Z, Zhao J, Ye X, Song Y, Wang Q, Hou G, Zhou Y, Li W, Ding L, Wang H, Chen Y, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Wang Z, Zhang H, Bu X, Zhang X, An L, Zhang S, Cao Z, Zhan Q, Yang Y, Liang L, Liu Z, Zhang X, Cheng A, Cao B, Dai H, Chung KF, He PMID 32598906
Identifiers
NCT: NCT07026370 · 2022-ZHCH330-01 · 2022-ZHCH330-01 · 2023FY100600 · 2016YFC1303900 · 201002008